Charles River Laboratories International, Inc.CRLNYSE
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -1.64% | -1.08% | -2.71% | +0.59% | -0.49% |
| Gross Profit Growth | -3.54% | -21.93% | -7.86% | +0.95% | -2.93% |
| EBITDA Growth | -6.99% | -126.79% | -16.02% | -7.38% | -5.70% |
| Operating Income Growth | -22.51% | -226.15% | -40.73% | -33.97% | +13.96% |
| Net Income Growth | -21.41% | -215.30% | -62.17% | -41.85% | -20.76% |
| EPS Growth | -21.18% | -215.62% | -61.83% | -39.43% | -17.16% |
| EPS Diluted Growth | -21.30% | -216.57% | -61.54% | -39.08% | -17.29% |
| Weighted Average Shares Growth | +0.22% | -0.34% | -1.48% | -4.66% | -4.24% |
| Weighted Average Shares Diluted Growth | -0.05% | -0.94% | -1.91% | -4.88% | -4.18% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +22.56% | -27.87% | +32.19% | +5.72% | -15.08% |
| Free Cash Flow Growth | +52.74% | -41.28% | +121.45% | +9.90% | -16.34% |
| Receivables Growth | -5.64% | -7.62% | -3.86% | +0.70% | -2.62% |
| Inventory Growth | +14.75% | -26.75% | -19.69% | -19.93% | -10.01% |
| Asset Growth | +5.22% | -8.13% | -7.00% | -4.88% | -6.12% |
| Book Value per Share Growth | +14.16% | -3.44% | -10.94% | -5.52% | -5.97% |
| Debt Growth | -5.00% | -11.17% | -3.01% | -1.83% | -4.65% |
| R&D Expense Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | +13.12% | -0.73% | -4.56% | +12.81% | -10.85% |